A Phase 2 Repeat-Dosing Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis

Study Purpose:

The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS

Study Status:

Not recruiting


Amyotrophic Lateral Sclerosis

Study Type:


Type of Intervention:


Intervention Name:




Phase 2

Study Chair(s)/Principal Investigator(s):

Ely Benaim, M.D., Sangamo Therapeutics

Clinicaltrials.gov ID:


Neals Affiliated?


Coordinating Center Contact Information

Sangamo Biosciences, Inc.

California, United States

Full Study Summary:

SB-509 contains the gene (DNA-a kind of biological "blueprint") for a protein. When a study doctor injects SB-509 into the muscles of your neck, arms and/or legs, the drug enters the muscle and nerve cells around the injection sites and causes these cells to make a protein. This protein causes your cells to increase production of one of your own protein called vascular endothelial growth factor(VEGF-A), which may improve the structure and function of nerves and muscles. In addition, there are changes in the levels of 28 additional proteins in your cells. These proteins function to promote the growth of cells, are structures in cells, help synthesize products, and affect immune cells, and some have unknown functions. This increase in your own VEGF proteins may protect and repair the damaged nerves and muscles caused by ALS.

Study Sponsor:

Sangamo Therapeutics

Estimated Enrollment:


Estimated Study Start Date:

08 / 31 / 2008

Estimated Study Completion Date:

06 / 01 / 2010

Posting Last Modified Date:

11 / 01 / 2012

Date Study Added to neals.org:

09 / 08 / 2008

Minimum Age:

18 Years

Maximum Age:

85 Years

Can participants use Riluzole?


Inclusion Criteria:

- Male or female between the ages of 18 and 85 with clinical diagnosis of ALS

- Forced Vital Capacity (FVC) > 60% of predicted

- Less than 3 years of ALS since the onset of the first symptom with clinical evidence of limb muscle atrophy and weakness.

- Subjects taking Riluzole must have been at a stable dose for at least 30 days with no evidence of toxicity

- Female of childbearing potential and male of child-creating potential must agree to use a medically acceptable physical barrier (condom, diaphragm, and cervical cap) through the treatment phase and for at least 30 days after the last study treatment.

Exclusion Criteria:

- Women who are pregnant or currently breast-feeding

- Dependent upon invasive or non-invasive artificial ventilation

- Patients with bulbar onset ALS or with other active neuromuscular/ neurodegenerative diseases.

- Type 1 or Type 2 diabetes.

- Evidence of chronic or active heart, liver, kidney, or lung diseases, or Age-related macular degeneration.

- Current or history of known immune or immunodeficiency disorders

- Patients with cognitive impairment with significant decision making incapacity, or major depression, or schizophrenia, or dementia (e.g. Alzheimer's disease).

- Malignancy or history of malignancy, except it has been in complete remission for at least 5 years

- Pre-cancerous conditions (e.g. Barrett's Esophagus, dysplasias) or benign tumors which have the potential for significant growth due to VEGF stimulation.

Coordinated Clinical Research

La Jolla, California 92037
United States

University of California, Irvine; MDA ALS and Neuromuscular Center,

Orange, California 92868
United States

California Pacific Medical Center (CPMC), The Forbes Norris MDA/ALS Research Center

San Francisco, California 94115
United States

The University of Kansas Medical Center (KU)

Kansas City, Kansas 66160
United States

Johns Hopkins University

Baltimore, Maryland 21287
United States

Nerve and Muscle Center of Texas

Houston, Texas 77030
United States